Ignite Creation Date:
2025-12-25 @ 12:32 AM
Ignite Modification Date:
2026-01-01 @ 7:23 AM
Study NCT ID:
NCT06962267
Status:
RECRUITING
Last Update Posted:
2025-05-08
First Post:
2025-04-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)
Sponsor:
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-04-18
Start Date Type:
ACTUAL
Primary Completion Date:
2027-08
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-10
Completion Date Type:
ESTIMATED
First Submit Date:
2025-04-30
First Submit QC Date:
None
Study First Post Date:
2025-05-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-30
Last Update Post Date:
2025-05-08
Last Update Post Date Type:
ACTUAL